Mustang Bio stock sits 2.70 percent above its yearly low

Published on 10/14/2026 at 03:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Mustang Bio stock last traded at USD 0.38 on October 13, 2026, versus USD 0.37 yearly low. Q2 2026 cash was USD 15.2 million.

Price and filings at a glance

Mustang Bio lists the second-quarter 2026 filing among its latest results.
The stock stood at USD 0.38 on October 13, 2026, against a USD 0.37 yearly low.
Mustang Bio reported a market capitalization of USD 2.9 million on October 13, 2026.

MBIO, US62818Q3020, Illustration mit AI erstellt.

Mustang Bio stock stood at USD 0.38 on Nasdaq on October 13, 2026, against a 52-week low of USD 0.37 and a 52-week high of USD 1.69. The clinical-stage biotechnology company lists its second-quarter 2026 filing among its latest financial results, giving investors a current reporting reference for the company.

Second-quarter filing sets the reference

Mustang Bio identifies the quarter ended June 30, 2026, as its latest financial-results period on the investor-relations site. The company says its work centers on translating cell-therapy research into potential treatments for difficult-to-treat cancers.

The company also describes a licensing and development model: it seeks rights to medical technologies, funds research and development, and may outlicense or bring those technologies to market. That structure makes clinical progress and funding capacity central to the investment case.

Cash and valuation remain central

Mustang Bio held USD 15.2 million in cash at the end of the second quarter of 2026. The company posted a net loss of USD 1.1 million for that period, while operating cash flow was negative USD 1.0 million, figures that place the cash balance against ongoing development spending.

At USD 0.38, the stock was 2.70 percent above its USD 0.37 yearly low and 77.51 percent below its USD 1.69 yearly high on October 13, 2026. The company had a market capitalization of USD 2.9 million on that date, keeping the share price highly sensitive to clinical and financing developments.

Nasdaq listing and next reference point

Mustang Bio trades under the ticker MBIO on Nasdaq. Its investor-relations page identifies the second-quarter filing dated June 30, 2026, as the latest financial-results reference, while the share's yearly range places the October 13 quotation near its low.

Market context: Market report Nasdaq Composite.